Literature DB >> 2699465

Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial.

A C Altamura1, F De Novellis, G Guercetti, G Invernizzi, M Percudani, S A Montgomery.   

Abstract

Twenty-eight elderly inpatients suffering from major depressive episodes (diagnosed according to DSM III) received randomly, on a double-blind basis, amitriptyline (75 mg/die) or fluoxetine (20 mg/die) for five weeks. There were four drop-outs in the amitriptyline group and two drop-outs in the fluoxetine group. Both groups showed a significant amelioration at the end point for Hamilton Rating Scale of Depression scores compared to the baseline value. Anticholinergic side-effects were significantly more severe in the amitriptyline group. Weight gain was detected only in patients receiving amitriptyline.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2699465

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  10 in total

Review 1.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

3.  Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression.

Authors:  Hadeer Emam; David C Steffens; Godfrey D Pearlson; Lihong Wang
Journal:  Int J Geriatr Psychiatry       Date:  2019-03-11       Impact factor: 3.485

4.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

Authors:  N Brynne; C Svanström; A Aberg-Wistedt; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 5.  Selective serotonin reuptake inhibitors for late-life depression: a comparative review.

Authors:  L K Solai; B H Mulsant; B G Pollock
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Authors:  I H Richard; M P McDermott; R Kurlan; J M Lyness; P G Como; N Pearson; S A Factor; J Juncos; C Serrano Ramos; M Brodsky; C Manning; L Marsh; L Shulman; H H Fernandez; K J Black; M Panisset; C W Christine; W Jiang; C Singer; S Horn; R Pfeiffer; D Rottenberg; J Slevin; L Elmer; D Press; H C Hyson; W McDonald
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

Review 7.  Fluoxetine versus other types of pharmacotherapy for depression.

Authors:  A Cipriani; P Brambilla; T Furukawa; J Geddes; M Gregis; M Hotopf; L Malvini; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 8.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

9.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

Authors:  F Song; N Freemantle; T A Sheldon; A House; P Watson; A Long; J Mason
Journal:  BMJ       Date:  1993-03-13

10.  Treatment of depression in late life.

Authors:  L S Schneider
Journal:  Dialogues Clin Neurosci       Date:  1999-09       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.